Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21097843
Nazarewicz RR, et al. (2011) Early endosomal antigen 1 (EEA1) is an obligate scaffold for angiotensin II-induced, PKC-alpha-dependent Akt activation in endosomes. J Biol Chem 286, 2886-95 21097843
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (rat)
Modsite: KDGATMKtFCGTPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase increase non caveolin early endosome fractions, caveolin fractions- no change compared to control
angiotensin_2 DYN1 (rat) inhibit treatment-induced increase dominant negative K$$A mutant inhibits
angiotensin_2 EEA1 (rat) increase EEA1 siRNA inhibits
PKCA (rat) increase PKCA siRNA inhibits

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase increase non caveolin early endosome fractions, caveolin fractions- no change compared to control
angiotensin_2 DYN1 (rat) inhibit treatment-induced increase dominant negative K$$A mutant inhibits
angiotensin_2 EEA1 (rat) increase EEA1 siRNA inhibits
PKCA (rat) increase PKCA siRNA inhibits

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase increase non caveolin early endosome fractions, caveolin fractions- no change compared to control
angiotensin_2 DYN1 (rat) inhibit treatment-induced increase dominant negative K$$A mutant inhibits
angiotensin_2 EEA1 (rat) increase EEA1 siRNA inhibits
PKCA (rat) increase PKCA siRNA inhibits

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase increase non caveolin early endosome fractions, caveolin fractions- no change compared to control
angiotensin_2 DYN1 (rat) inhibit treatment-induced increase dominant negative K$$A mutant inhibits
angiotensin_2 EEA1 (rat) increase EEA1 siRNA inhibits
PKCA (rat) increase PKCA siRNA inhibits

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  VSMC
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase increase non caveolin early endosome fractions, caveolin fractions- no change compared to control
angiotensin_2 DYN1 (rat) inhibit treatment-induced increase dominant negative K$$A mutant inhibits
angiotensin_2 EEA1 (rat) increase EEA1 siRNA inhibits

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  VSMC
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase increase non caveolin early endosome fractions, caveolin fractions- no change compared to control
angiotensin_2 DYN1 (rat) inhibit treatment-induced increase dominant negative K$$A mutant inhibits
angiotensin_2 EEA1 (rat) increase EEA1 siRNA inhibits

S2448-p - mTOR (rat)
Modsite: RSRTRTDsYSAGQSV SwissProt Entrez-Gene
Orthologous residues
mTOR (human): S2448‑p, mTOR (mouse): S2448‑p, mTOR (rat): S2448‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  VSMC
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase
EEA1 (human) increase EEA1 siRNA inhibits

T180-p - P38A (rat)
Modsite: RHTDDEMtGyVATRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  VSMC
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase
EEA1 (human) increase EEA1 siRNA inhibits
PKCA (rat) increase PKCA siRNA inhibits

Y182-p - P38A (rat)
Modsite: TDDEMtGyVATRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  VSMC
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase
EEA1 (human) increase EEA1 siRNA inhibits
PKCA (rat) increase PKCA siRNA inhibits

T412-p - p70S6K (rat)
Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  VSMC
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
angiotensin_2 increase
EEA1 (human) increase EEA1 siRNA inhibits

S244-p - PDK1 (rat)
Modsite: SKQARANsFVGTAQY SwissProt Entrez-Gene
Orthologous residues
PDK1 (human): S241‑p, PDK1 iso2 (human): S191‑p, PDK1 iso4 (human): S114‑p, PDK1 iso5 (human): S241‑p, PDK1 (mouse): S244‑p, PDK1 (rat): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  VSMC
Cellular systems studied:  cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PKCA (rat) increase PKCA siRNA inhibits